Borghaei and Gunuganti Break Down the Elements of Treatment Selection in NSCLC

December 17, 2020
OncLive Staff

Partner | Cancer Centers | <b>Fox Chase</b>

In our exclusive interview, Dr. Borghaei and Dr. Gunuganti discuss patient selection for frontline immunotherapy, combination immunotherapy, and chemoimmunotherapy in NSCLC, the importance of PD-L1 expression, and emerging agents that are coming down the pike.

Welcome to OncLive On Air! I’m your host today, Caroline Seymour.

OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, sponsored by Bristol Myers Squibb, we had the pleasure of speaking with Hossein Borghaei, DO, chief of the Division of Thoracic Medical Oncology, director of Lung Cancer Risk Assessment, and associate professor within the Department of Hematology/Oncology at Fox Chase Cancer Center, and Vijay K. Gunuganti, MD, an adjunct faculty member in the Division of Medical Oncology at the University of Texas Health San Antonio, as well as a hematologist and medical oncologist at Texas Oncology–San Antonio Northeast, to discuss current frontline treatment options in advanced, driver-negative non–small cell lung cancer (NSCLC).

In our exclusive interview, Borghaei and Gunuganti discussed patient selection for frontline immunotherapy, combination immunotherapy, and chemoimmunotherapy in NSCLC, the importance of PD-L1 expression, and emerging agents that are coming down the pike.

Related Content:

Fox Chase | Podcasts | Lung Cancer

x